These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

687 related items for PubMed ID: 25453957

  • 1. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
    Chung SW, Bae SM, Lee M, Al-Hilal TA, Lee CK, Kim JK, Kim IS, Kim SY, Byun Y.
    Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
    [Abstract] [Full Text] [Related]

  • 2. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor.
    Lee E, Kim YS, Bae SM, Kim SK, Jin S, Chung SW, Lee M, Moon HT, Jeon OC, Park RW, Kim IS, Byun Y, Kim SY.
    Int J Cancer; 2009 Jun 15; 124(12):2755-65. PubMed ID: 19243020
    [Abstract] [Full Text] [Related]

  • 3. Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor.
    Adulnirath A, Chung SW, Park J, Hwang SR, Kim JY, Yang VC, Kim SY, Moon HT, Byun Y.
    J Control Release; 2012 Nov 28; 164(1):8-16. PubMed ID: 23063549
    [Abstract] [Full Text] [Related]

  • 4. Enhanced Anti-Angiogenic Effect of Low Molecular Weight Heparin-Bile Acid Conjugates by Co-Administration of a Selective COX-2 Inhibitor.
    Kim JY, Chung SW, Kim SY, Byun Y.
    Pharm Res; 2015 Jul 28; 32(7):2318-27. PubMed ID: 25585956
    [Abstract] [Full Text] [Related]

  • 5. Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy.
    Alam F, Al-Hilal TA, Chung SW, Park J, Mahmud F, Seo D, Kim HS, Lee DS, Byun Y.
    J Control Release; 2015 Jan 10; 197():180-9. PubMed ID: 25445701
    [Abstract] [Full Text] [Related]

  • 6. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.
    Alam F, Al-Hilal TA, Chung SW, Seo D, Mahmud F, Kim HS, Kim SY, Byun Y.
    Biomaterials; 2014 Aug 10; 35(24):6543-52. PubMed ID: 24816287
    [Abstract] [Full Text] [Related]

  • 7. An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties.
    Bae SM, Kim JH, Chung SW, Byun Y, Kim SY, Lee BH, Kim IS, Park RW.
    Biomaterials; 2013 Mar 10; 34(8):2077-86. PubMed ID: 23245333
    [Abstract] [Full Text] [Related]

  • 8. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.
    Eur Cytokine Netw; 2009 Dec 10; 20(4):225-34. PubMed ID: 20167562
    [Abstract] [Full Text] [Related]

  • 9. Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor.
    Alam F, Chung SW, Hwang SR, Kim JY, Park J, Moon HT, Byun Y.
    J Appl Toxicol; 2015 Jan 10; 35(1):104-15. PubMed ID: 24532548
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.
    Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT.
    Am J Pathol; 2006 Jun 10; 168(6):2036-53. PubMed ID: 16723717
    [Abstract] [Full Text] [Related]

  • 11. Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge.
    Chung SW, Lee M, Bae SM, Park J, Jeon OC, Lee HS, Choe H, Kim HS, Lee BS, Park RW, Kim SY, Byun Y.
    Biomaterials; 2012 Dec 10; 33(35):9070-9. PubMed ID: 23010574
    [Abstract] [Full Text] [Related]

  • 12. A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.
    Tate CM, Mc Entire J, Pallini R, Vakana E, Wyss L, Blosser W, Ricci-Vitiani L, D'Alessandris QG, Morgante L, Giannetti S, Larocca LM, Todaro M, Benfante A, Colorito ML, Stassi G, De Maria R, Rowlinson S, Stancato L.
    PLoS One; 2015 Dec 10; 10(4):e0125697. PubMed ID: 25919028
    [Abstract] [Full Text] [Related]

  • 13. Differential role of platelet granular mediators in angiogenesis.
    Brill A, Elinav H, Varon D.
    Cardiovasc Res; 2004 Aug 01; 63(2):226-35. PubMed ID: 15249180
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC, Scicli GM, McMahon G, Scicli AG.
    Microvasc Res; 2002 May 01; 63(3):304-15. PubMed ID: 11969307
    [Abstract] [Full Text] [Related]

  • 15. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2006 Jan 15; 12(2):634-42. PubMed ID: 16428510
    [Abstract] [Full Text] [Related]

  • 16. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling.
    Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K, Miyazawa K.
    J Cell Sci; 2005 Aug 15; 118(Pt 16):3759-68. PubMed ID: 16105884
    [Abstract] [Full Text] [Related]

  • 17. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X, Wang X, Ye H, Peng A, Chen L.
    Cancer Chemother Pharmacol; 2012 Sep 15; 70(3):425-37. PubMed ID: 22814678
    [Abstract] [Full Text] [Related]

  • 18. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
    Li D, Xie K, Zhang L, Yao X, Li H, Xu Q, Wang X, Jiang J, Fang J.
    Cancer Lett; 2016 Jul 28; 377(2):164-73. PubMed ID: 27130666
    [Abstract] [Full Text] [Related]

  • 19. Comparison of Topical Low-Molecular-Weight Heparin-Taurocholate and Bevacizumab for Treatment and Prevention of Corneal Neovascularization.
    Moon CH, Moon BG, Kim JY, Kim MJ, Tchah H.
    Cornea; 2017 Apr 28; 36(4):497-501. PubMed ID: 27941385
    [Abstract] [Full Text] [Related]

  • 20. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.
    Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Bråkenhielm E, Cao Y.
    J Clin Invest; 2007 Oct 28; 117(10):2766-77. PubMed ID: 17909625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.